Merck, a leading science and technology company, today enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan,
The company offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. Financial details of the acquisition were not disclosed.
'This acquisition supports our vision of delivering intensified, connected and continuous bioprocessing,' said
RESOLUTION
Measure broad range of bioprocessing parameters, including glucose, lactate, viable cell density and other process-related impurities.
Monitor all parameters simultaneously with a single probe.
This acquisition supports Merck's recently launched Bio4C Software Suite, a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. The Bio4C Software Suite is the latest component of Merck's expanding BioContinuum Platform, which allows for the convergence of intensified process and digital technologies to advance process speed, quality and flexibility, while reducing cost.
Raman technology's bioprocess monitoring sensors complement the 'collect' dimension of the Bio4C Software Suite, as it provides real-time process analytics across multiple critical process parameters via in-line measurement. By combining these Raman technology sensors with the software to manage the data that they provide, Merck is able to offer unique and integrated bioprocessing capabilities.
The acquisition of RESOLUTION Spectra Systems enhances Merck's ability to provide advanced process analytical technologies across its bioprocess portfolio, another critical step toward enabling the biomanufacturing facility of the future.
Contact:
Tel: +49 6151 72-44461
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck generated sales of
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are
(C) 2020 Electronic News Publishing, source